- Home
- AIO vs SYRE Comparison
AIO vs SYRE Comparison
Compare AIO & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIO
- SYRE
- Stock Information
- Founded
- AIO 2019
- SYRE 2013
- Country
- AIO United States
- SYRE United States
- Employees
- AIO N/A
- SYRE N/A
- Industry
- AIO Finance/Investors Services
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- AIO Finance
- SYRE Health Care
- Exchange
- AIO Nasdaq
- SYRE Nasdaq
- Market Cap
- AIO 808.3M
- SYRE 841.4M
- IPO Year
- AIO N/A
- SYRE 2016
- Fundamental
- Price
- AIO $24.67
- SYRE $16.12
- Analyst Decision
- AIO
- SYRE Buy
- Analyst Count
- AIO 0
- SYRE 6
- Target Price
- AIO N/A
- SYRE $55.00
- AVG Volume (30 Days)
- AIO 141.5K
- SYRE 630.9K
- Earning Date
- AIO 01-01-0001
- SYRE 08-06-2025
- Dividend Yield
- AIO 9.05%
- SYRE N/A
- EPS Growth
- AIO N/A
- SYRE N/A
- EPS
- AIO N/A
- SYRE N/A
- Revenue
- AIO N/A
- SYRE N/A
- Revenue This Year
- AIO N/A
- SYRE N/A
- Revenue Next Year
- AIO N/A
- SYRE N/A
- P/E Ratio
- AIO N/A
- SYRE N/A
- Revenue Growth
- AIO N/A
- SYRE N/A
- 52 Week Low
- AIO $15.09
- SYRE $10.91
- 52 Week High
- AIO $20.25
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- AIO 60.09
- SYRE 57.17
- Support Level
- AIO $24.09
- SYRE $15.05
- Resistance Level
- AIO $24.78
- SYRE $17.09
- Average True Range (ATR)
- AIO 0.31
- SYRE 1.00
- MACD
- AIO -0.06
- SYRE 0.12
- Stochastic Oscillator
- AIO 66.67
- SYRE 91.05
About AIO Virtus Artificial Intelligence & Technology Opportunities Fund of Beneficial Interest
Virtus Artificial Intelligence & Technology Opportunities Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.